Literature DB >> 35662756

Transient Hepatitis Secondary to Zoledronic Acid in a Woman with Sheehan Syndrome.

Bashir A Laway1, Sajad Ul Islam Mir1, Mir Iftikhar Bashir1.   

Abstract

Entities:  

Year:  2022        PMID: 35662756      PMCID: PMC9162249          DOI: 10.4103/ijem.ijem_484_21

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


× No keyword cloud information.
Sir, Patients with Sheehan syndrome (SS) have low bone mineral density mainly because of gonadotroph and somatotroph deficiency together with long-term thyroxine and glucocorticoid treatment.[12] Bisphosphonates along with calcium and vitamin D supplementation are commonly used for the treatment of osteoporosis. Zoledronic acid (ZA) prescribed as yearly infusion is safe and well tolerated except transient and self-limiting flu-like symptoms. Here, we report a patient of SS who developed mild transient hepatitis after ZA infusion. A 55-year-old woman was diagnosed with SS 6 years back based on post-partum haemorrhage, lactotroph, gonadotroph, thyrotroph and corticotroph failure and empty sella on MR imaging. She was prescribed thyroxine (75 micrograms daily) and prednisolone (5 milligrams daily) along with elemental calcium of 500 mgs and 1000 units of cholecalciferol daily. DXA scan revealed osteoporosis (T-score L1-L4 spine = -3.9). She is a non-smoker, does not consume alcohol and did not take any other drug causing liver disease. Her baseline liver function test (LFT) was within normal limits [Table 1]. The patient received injection ZA, 5 mgs in 100 ml of ready-to-infuse solution (Stoplos One 5 mgs/100 ml; Akums Drugs and Pharmaceuticals Ltd., Haridwar, India) over a period of 30 minutes. Few hours after the infusion, she experienced flu-like symptoms; these symptoms continued on the second day. On the second day, clinical examination revealed an icteric tinge. LFT revealed hyperbilirubinemia with elevated liver enzymes, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT) [Table 1]. Ultrasound revealed evidence of grade 1 fatty liver without any focal lesion of liver parenchyma and biliary tract. A diagnosis of acute hepatitis was considered, and she was further investigated for the aetiology of hepatitis. Serological tests for hepatitis A, B, E and C were negative, ruling out the possibility of viral hepatitis. Meanwhile, C-reactive protein (CRP), antinuclear antibody–indirect fluorescent antibody (ANA-IFA), anti-mitochondrial antibody (AMA) and anti-smooth muscle antibody were negative, ruling out the possibility of autoimmune hepatitis [Table 1]. In view of a normal LFT before ZA infusion, clinical jaundice, abnormal liver enzymes, negative viral and autoimmune screen, possibility of drug-induced liver injury secondary to ZA was entertained. The patient was managed conservatively and was kept in hospital for observation. The patient had a normal appetite and did not need parental fluids. LFTs were repeated at days 3, 5 and 6, which revealed a downward trend and finally normalization of liver enzymes on day 6.
Table 1

Serial liver function tests in the patient with zoledronic acid-induced hepatitis

ParameterNormal valuePre-treatmentDay 1Day 3Day 5Day 6
Bilirubin0.30-1.50 (mg/dl)1.63.53.81.581.36
AST0-40 (U/L)30120--31
ALT0-45 (U/L)221261317853
ALP30-141 (U/L)-104869981
GGT2-55 (U/L)-195--169
Albumin3.50-5.20 (g/dl)4.794.954.654.404.56
WBC4-11 (/µL)4900690067008200-
CRP<6 (mg/L)--<6--
ANA-IFA(1:80 dilution)--Negative--
AMA< 20 (IU/mL)--11.14--
ASMA<20 (IU/mL)-12.69--

AST=aspartate aminotransferase, ALT=alanine aminotransferase, ALP=alkaline phosphatase, GGT=gamma-glutamyl transpeptidase, WBC=white blood cell count, CRP=C-reactive protein, ANA-IFA=antinuclear antibody–indirect fluorescent antibody, AMA=anti-mitochondrial antibody, ASMA=anti-smooth muscle antibody

Serial liver function tests in the patient with zoledronic acid-induced hepatitis AST=aspartate aminotransferase, ALT=alanine aminotransferase, ALP=alkaline phosphatase, GGT=gamma-glutamyl transpeptidase, WBC=white blood cell count, CRP=C-reactive protein, ANA-IFA=antinuclear antibody–indirect fluorescent antibody, AMA=anti-mitochondrial antibody, ASMA=anti-smooth muscle antibody As many as one-third of ZA-naïve patients experience an acute phase reaction manifesting as fever, myalgia, headache or other flu-like symptoms. The other rare potential side effects of ZA are atrial fibrillation, uveitis, osteonecrosis of the jaw (ONJ) and atypical femoral fracture.[3] Few cases of drug-induced liver injury because of ZA are reported. The liver injury may be mild and transient or severe and recurrent requiring glucocorticoids.[456] Our patient had a mild and transient liver injury, which resolved within a week. Idiosyncratic sensitivity to ZA may be the cause of liver injury in the present patient. The clinical significance of mild and transient liver injury may be mild, but clinicians should be aware of this adverse effect, and it may be advisable to get a routine LFT performed before administering a dose of ZA.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  6 in total

Review 1.  Sheehan syndrome.

Authors:  Züleyha Karaca; Bashir A Laway; Hatice S Dokmetas; Hulusi Atmaca; Fahrettin Kelestimur
Journal:  Nat Rev Dis Primers       Date:  2016-12-22       Impact factor: 52.329

2.  Decreased bone mineral density in women with Sheehan's syndrome and improvement following oestrogen replacement and nutritional supplementation.

Authors:  Purnima Agarwal; Ramesh Gomez; Eesh Bhatia; Subhash Yadav
Journal:  J Bone Miner Metab       Date:  2018-02-20       Impact factor: 2.626

3.  Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.

Authors:  S A Polyzos; J Kountouras; A D Anastasilakis; I Litsas; M Kita; G Arsos; E Moralidis; E Terpos
Journal:  Osteoporos Int       Date:  2010-04-21       Impact factor: 4.507

Review 4.  Update on Rare Adverse Events from Osteoporosis Therapy and Bisphosphonate Drug Holidays.

Authors:  Robert A Adler
Journal:  Endocrinol Metab Clin North Am       Date:  2021-04-28       Impact factor: 4.741

5.  Drug-Induced Autoimmune Hepatitis following Treatment with Zoledronic Acid.

Authors:  Jenny Sarah Schneider; Matteo Montani; Felix Stickel
Journal:  Case Rep Gastroenterol       Date:  2017-08-08

6.  Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis.

Authors:  Yanhui Lu; Yu Pei; Yinghong Shao; Shuangtong Yan; Lichao Ma; Fusheng Fang; Mengmeng Jin; Minyan Liu; Jian Li; Chunlin Li
Journal:  EXCLI J       Date:  2013-02-13       Impact factor: 4.068

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.